Molecular Oncology is published by Elsevier on behalf of the Federation of European Biochemical Societies
Molecular Oncology highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational research. Topics include:
• Key biological processes such as cell cycle; DNA repair; apoptosis; invasion and metastasis; angiogenesis and lymphangiogenesis; cell signalling and interactive networks; immune response.
• Emerging technologies (genomics, proteomics, functional genomics, metabolomics, tissue arrays, imaging), and model systems.
•Biomarkers: diagnosis, prognosis, stratification and efficacy.
• Cancer genetics, epigenetics, and genomic instability.
• Minimal residual disease, pre-malignant lesions.
• Cancer micro-environment.
• Molecular pathology.
• Tumour immunology.
• Translational research.
• Cancer therapy (target discovery, drug design, immunotherapy, combination therapies, resistance, and individualised treatment).
• Chemotherapy, radiotherapy and surgery.
• Clinical pharmacology.
• Clinical trials, integration of basic science into cancer clinical trials.
• Epidemiology and prevention.
• Infrastructures (biobanks, databases, genomic resources).
A main feature of the Journal is to provide an international forum for debating cancer issues, and for integrating the input of all the stakeholders.
Coverage: Reviews, original articles, technical notes, editorials, news & views (commentary, science policy issues, ethical and legal issues, patient organisations, industry needs and alliances, regulatory issues, news items), letters to the editor, conference announcements, advertisements.Submitting Authors:
Manuscripts can be submitted to Molecular Oncology at:http://ees.elsevier.com/molonc/
Editor in Chief: J.E. Celis
- Imprint: ELSEVIER
- ISSN: 1574-7891